Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02657434 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 578
- Enrollment target
NCT02657434 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 578 participants.
The verdict
NCT02657434, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 578 participants
- Enrollment target
Study Summary
This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase.
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Cisplatin
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 578 participants |
| Start Date | 2016-04-30 |
| Est. Completion | 2022-12-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02657434
The ClinicalTrials.gov registry entry for NCT02657434 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 578 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT02657434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02657434 about?
NCT02657434 is a clinical study titled "A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)". This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have...
What is the current status of trial NCT02657434?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 578 participants. The study started on 2016-04-30. Estimated completion is 2022-12-13.
What interventions are being tested in trial NCT02657434?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT02657434?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.